

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	TBA/Continuation of 08/390,474
Filing Date	September 28, 2001
First Named Inventor	KINZLER et al.
Prior Group Art Unit	1632
Prior Examiner Name	S. Priebe
Attorney Docket Number	01107.00193

1c997 U.S. PTO

09/966724



10701701

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Fakharzadeh, et al., "Tumorigenic Potential Associated with Enhanced Expression of a Gene That is Amplified in a Mouse Tumor Cell Line", <u>The EMBO Journal</u> , 10(6):1565-1569 (1991)	
		Hinds, et al., "Mutant p53 DNA Clones From Human Colon Carcinomas Cooperate with Ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes", <u>Cell Growth & Differentiation</u> , 1:561-580 (1990)	
		Romkes, et al., "Cloning and Expression of cDNA for Multiple Members of the Human Cytochrome P45011C Subfamily", <u>Biochemistry</u> , 30(13):3247-3255 (1991)	
		Momand, et al., "The MDM2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation", <u>Cell</u> , 69:1237-1245 (1992)	
DP		Oliner, et al., "Amplification of a Gene Encoding a p53-Associated Protein in Human Sarcomas", <u>Nature</u> , 358:80-83 (1992)	
		Ladanyi, et al., "MDM2 Gene Amplification in Metastatic Osteosarcoma", <u>Cancer Research</u> , 53:2231-2234 (1993)	
		Oliner, et al., "Oncoprotein MDM2 Conceals the Activation Domain of Tumour Suppressor p53", <u>Nature</u> , 362(6423):857-860 (1993)	
		Cahilly, et al., "Molecular Analysis and Chromosomal Mapping of Amplified Genes Isolated from a Transformed Mouse 3T3 Cell Line", <u>Somatic Cell and Molecular Genetics</u> , 13(3):235-244 (1987)	
		Hodgson, <u>Exp. Opin. Ther. Pat.</u> , 5(5), 1995, 459-468	
		Uhlmann et al., <u>Chem. Rev.</u> , 90(4), 1990, 544-584	
DP		Culver et al., <u>TIG</u> , 10(5), 1994, 174-178	
		Leach, et al., "p53 Mutation and MDM2 Amplification in Human Soft Tissue Sarcomas", <u>Cancer Research</u> , 53:2231-2234 (1993)	

Examiner Signature

[Handwritten Signature]

Date Considered

02/10/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)


Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Application Number		TBA/Continuation of 08/390,474			
Filing Date		September 28, 2001			
First Named Inventor		KINZLER et al.			
Group Art Unit		1632			
Examiner Name		S. Priebe			
Attorney Docket Number		01107.00193			
Sheet	2	of	2		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Narayanan et al., <u>Oncogene</u> , 1992, 7(3), 553-561	
		Levine et al., <u>Nature</u> , 351, 1991, 453-456	
DM		Marshall, <u>Science</u> , 269, 1995, 1050-1055	
		Stein et al., <u>Science</u> , 261, 1993, 1004-1012	
		Wu-Pong, <u>Pharm. Tech.</u> , 18, 1994, 102-114	
DM		Miller et al., <u>FASEB</u> , 9, 1995, 190-199	
MP		Rojanasakul, <u>Ad. Drug. Del. Rev.</u> , 18 (1996), 115-131	
		Miller, <u>J. Med. Chem.</u> , 36(14), 1423-1437, 1993	

Examiner Signature		Date Considered	02/10/05
-----------------------	---	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.